| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 |
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Tyra Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
90240B106
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 90240B106 | |||||
| 1. | Names
of Reporting Persons Nextech VI Oncology SCSp | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | ¨ | ||||
| (b) | x(1) | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship
or Place of Organization Luxembourg | ||||
| Number
of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole
Voting Power 4,055,861 shares | |||
| 6. | Shared
Voting Power 0 | ||||
| 7. | Sole
Dispositive Power 4,055,861 shares | ||||
| 8. | Shared
Dispositive Power 0 | ||||
| 9. | Aggregate
Amount Beneficially Owned by Each Reporting Person 4,055,861 shares | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | ||||
| 11. | Percent
of Class Represented by Amount in Row (9) 7.7% (2) | ||||
| 12. | Type
of Reporting Person (See Instructions) PN | ||||
| (1) | This Schedule 13G is filed by Nextech VI Oncology SCSp (“Nextech VI LP”), Nextech VI GP S.à r.l. (“Nextech VI GP”), Ian Charoub (“Charoub”), Costas Constantinides (“Constantinides”) and Rocco Sgobbo (“Sgobbo” and, with Nextech VI LP, Nextech VI GP, Charoub and Constantinides, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
2
| CUSIP No. 90240B106 | |||||
| 1. | Names of Reporting Persons Nextech VI GP S.à r.l. | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | ¨ | ||||
| (b) | x(1) | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Luxembourg | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 4,055,861 shares | |||
| 6. | Shared Voting Power 0 | ||||
| 7. | Sole Dispositive Power 4,055,861 shares | ||||
| 8. | Shared Dispositive Power 0 | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 4,055,861 shares | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.7% (2) | ||||
| 12. | Type of Reporting Person (See Instructions) OO | ||||
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
3
| CUSIP No. 90240B106 | |||||
| 1. | Names of Reporting Persons Ian Charoub | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | ¨ | ||||
| (b) | x (1) | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Sweden | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 | |||
| 6. | Shared Voting Power 4,055,861 shares | ||||
| 7. | Sole Dispositive Power 0 | ||||
| 8. | Shared Dispositive Power 4,055,861 shares | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 4,055,861 shares | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.7% (2) | ||||
| 12. | Type of Reporting Person (See Instructions) IN | ||||
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
4
| CUSIP No. 90240B106 | |||||
| 1. | Names of Reporting Persons Costas Constantinides | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | ¨ | ||||
| (b) | x (1) | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Cyprus | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 | |||
| 6. | Shared Voting Power 4,055,861 shares | ||||
| 7. | Sole Dispositive Power 0 | ||||
| 8. | Shared Dispositive Power 4,055,861 shares | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 4,055,861 shares | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.7% (2) | ||||
| 12. | Type of Reporting Person (See Instructions) IN | ||||
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
5
| CUSIP No. 90240B106 | |||||
| 1. | Names of Reporting Persons Rocco Sgobbo | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | ¨ | ||||
| (b) | x (1) | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Switzerland | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 | |||
| 6. | Shared Voting Power 4,055,861 shares | ||||
| 7. | Sole Dispositive Power 0 | ||||
| 8. | Shared Dispositive Power 4,055,861 shares | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 4,055,861 shares | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.7% (2) | ||||
| 12. | Type of Reporting Person (See Instructions) IN | ||||
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
6
| Item 1. | ||
| (a) | Name of Issuer:
Tyra Biosciences, Inc. | |
| (b) | Address of Issuer’s Principal Executive Offices:
2656 State Street | |
| Item 2. | ||
| (a) | Name of Reporting Persons Filing:
Nextech VI Oncology SCSp (“Nextech VI LP”) Nextech VI GP S.à r.l. (“Nextech VI GP”) Ian Charoub (“Charoub”) Costas Constantinides (“Constantinides”) Rocco Sgobbo (“Sgobbo”) | |
| (b) | Address of Principal Business Office or, if none, Residence:
8 rue Lou Hemmer L-1748 Luxembourg-Findel Grand-Duché de Luxembourg | |
| (c) | Citizenship | ||||
| Entities: | Nextech VI Oncology SCSp | - | Luxembourg | ||
| Nextech VI GP S.à r.l. | - | Luxembourg | |||
| Individuals: | Ian Charoub | - | Sweden | ||
| Costas Constantinides | - | Cyprus | |||
| Rocco Sgobbo | - | Switzerland |
| (d) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (e) | CUSIP Number:
90240B106 | |
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| Not applicable | ||
7
| Item 4. | Ownership |
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of November 14, 2024: | |
| Reporting Persons | Shares Held Directly | Sole Voting Power | Shared Voting Power (1) | Sole Dispositive Power | Shared Dispositive Power (1) | Beneficial Ownership | Percentage of Class (1) (2) | |||||||||||||||
| Nextech VI LP | 4,055,861 | 4,055,861 | 0 | 4,055,861 | 0 | 4,055,861 | 7.7 | % | ||||||||||||||
| Nextech VI GP (1) | 0 | 4,055,861 | 0 | 4,055,861 | 0 | 4,055,861 | 7.7 | % | ||||||||||||||
| Charoub (1) | 0 | 0 | 4,055,861 | 0 | 4,055,861 | 4,055,861 | 7.7 | % | ||||||||||||||
| Constantinides (1) | 0 | 0 | 4,055,861 | 0 | 4,055,861 | 4,055,861 | 7.7 | % | ||||||||||||||
| Sgobbo (1) | 0 | 0 | 4,055,861 | 0 | 4,055,861 | 4,055,861 | 7.7 | % | ||||||||||||||
(1) The shares are held by Nextech VI LP. Nextech VI GP serves as the sole general partner of Nextech VI LP and has sole voting and investment control over the shares owned by Nextech VI LP and may be deemed to own beneficially the shares held by Nextech VI LP. Nextech VI GP owns no securities of the Issuer directly. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech VI GP and share voting and dispositive power over the shares held by Nextech VI LP, and may be deemed to own beneficially the shares held by Nextech VI LP. The members of the board of managers own no securities of the Issuer directly.
(2) The percent of class was calculated based on 52,806,137 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. |
| Item 5. | Ownership of Five Percent or Less of a Class |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| Not applicable | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| Not applicable | |
| Item 8. | Identification and Classification of Members of the Group |
| Not applicable | |
| Item 9. | Notice of Dissolution of Group |
| Not applicable | |
| Item 10. | Certification |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. | |
8
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: November 14, 2024 | ||
| Nextech VI Oncology SCSp | ||
| By: | Nextech VI GP S.à r.l. | |
| its | General Partner | |
| By: | /s/ Ian Charoub | |
| Ian Charoub, Manager | ||
| By: | /s/ Costas Constantinides | |
| Costas Constantinides, Manager | ||
| Nextech VI GP S.à r.l. | ||
| By: | /s/ Ian Charoub | |
| Ian Charoub, Manager | ||
| By: | /s/ Costas Constantinides | |
| Costas Constantinides, Manager | ||
| /s/ Ian Charoub | ||
| Ian Charoub | ||
| /s/ Costas Constantinides | ||
| Costas Constantinides | ||
| /s/ Rocco Sgobbo | ||
| Rocco Sgobbo | ||
| ATTENTION | ||
| Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||
9
Exhibit(s):
Exhibit 99.A
EXHIBIT A
JOINT FILING STATEMENT
We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the
Common Stock of Tyra Biosciences, Inc. is filed on behalf of each of us.
| Dated: November 14, 2024 | ||
| Nextech VI Oncology SCSp | ||
| By: | Nextech VI GP S.à r.l. | |
| its | General Partner | |
| By: | /s/ Ian Charoub | |
| Ian Charoub, Manager | ||
| By: | /s/ Costas Constantinides | |
| Costas Constantinides, Manager | ||
| Nextech VI GP S.à r.l. | ||
| By: | /s/ Ian Charoub | |
| Ian Charoub, Manager | ||
| By: | /s/ Costas Constantinides | |
| Costas Constantinides, Manager | ||
| /s/ Ian Charoub | ||
| Ian Charoub | ||
| /s/ Costas Constantinides | ||
| Costas Constantinides | ||
| /s/ Rocco Sgobbo | ||
| Rocco Sgobbo | ||